Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:531752 vs MS, GS, SCHW: Buyback Yield % Comparison
For the Capital Markets subindustry, Biogen Pharmachem Industries's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogen Pharmachem Industries Buyback Yield % vs Capital Markets Industry
For the Capital Markets industry and Financial Services sector, Biogen Pharmachem Industries's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Biogen Pharmachem Industries's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biogen Pharmachem Industries (BOM:531752) has a Buyback Yield % of -21.37 as of Aug. 11, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Biogen Pharmachem Industries and its competitors. According to the industry distribution chart, Biogen Pharmachem Industries ranks #196 out of 246 companies in the Capital Markets industry, placing it in the top 79.7%.
Is Biogen Pharmachem Industries' Buyback Yield % too high?
Biogen Pharmachem Industries' current Buyback Yield % is -21.37. Based on the distribution chart, Biogen Pharmachem Industries ranks #196 out of 246 companies in the Capital Markets industry, which is in the bottom quartile relative to peers. Overall, Biogen Pharmachem Industries has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Biogen Pharmachem Industries' Buyback Yield % compare to MS and GS?
According to the Capital Markets industry distribution chart, Biogen Pharmachem Industries ranks #196 out of 246 companies for Buyback Yield %. This places Biogen Pharmachem Industries in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Capital Markets company?
A good Buyback Yield % depends on the Capital Markets industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Biogen Pharmachem Industries and its competitors. Biogen Pharmachem Industries's current Buyback Yield % is -21.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen Pharmachem Industries stock overvalued right now?
Biogen Pharmachem Industries (BOM:531752) has a current Buyback Yield % of -21.37. The current Buyback Yield % is -21.37. Biogen Pharmachem Industries' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Biogen Pharmachem Industries (BOM:531752), the current Buyback Yield % is -21.37 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531752 has been successfully added to your 
